PCV14: RACIAL VARIATION IN THE UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS: AN ANALYSIS OF 1998 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA  by Yang, Y & Waters, TM
311Abstracts
reports of prosthetic heart valve thromboses while on
enoxaparin, the medication is no longer recommended 
for this indication. The objective of this research was to
examine the relationship between the use of enoxaparin
for TBX in patients with mechanical heart valves and
negative health outcomes. METHODS: Data were retro-
spectively obtained from a hospital-based anticoagulation
clinic database between January 1998 and July 2002.
RESULTS: Twenty patients (13 mitral valve replacement
[MVR], 6 aortic valve replacement [AVR], and 1 combi-
nation [MVR/AVR]) representing 36 encounters were
identiﬁed. Eighteen patients had multiple co-morbid 
conditions that further increased their risk for thrombus
formation including: atrial ﬁbrillation, congestive heart
failure, previous stroke, and cancer. All patients received
enoxaparin 1mg/kg every 12 hours. Enoxaparin was used
for TBX as bridging therapy associated with sub-optimal
COA. Reasons for a sub-optimal anticoagulation with
warfarin included non-adherence to warfarin therapy
and/or a low vitamin K diet, or a suboptimal dose of 
warfarin. In 35 of 36 patient encounters, no evidence of
thromboembolic events occurred during bridging therapy
with enoxaparin. One patient developed left hemian-
opsia and blurred vision approximately 3–4 hours after
beginning enoxaparin therapy. Prior to beginning enoxa-
parin therapy, the patient’s INR was 1.39; the duration
of sub-therapeutic COA in this patient is unknown. It
could not be determined if this event was due to an inad-
equate level of anticoagulation provided by enoxaparin
or inadequate anticoagulation with warfarin prior to
receiving enoxaparin. CONCLUSION: Enoxaparin was
an effective agent for thromboprophylaxis in patients
with mechanical heart valves requiring bridging therapy
for sub-therapeutic chronic oral anticoagulation in this
population. Further research is required to conﬁrm these
ﬁndings.
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OBJECTIVES: Prior studies have shown that wide vari-
ations in the management of hypertension among differ-
ent racial groups exist. The objective of our study is to
explore the racial variations in the utilization of different
classes of antihypertensive pharmaceuticals after adjust-
ing for confounding factors. METHODS: We identiﬁed
2692 individuals diagnosed with hypertension from 1998
MEPS Household Component by their ICD-9 code. The
use of antihypertensive medications were classiﬁed into
six categories and one no treatment category. Logistic
regressions were used to adjust for demographics, socioe-
conomic status, insurance, and coexisting diseases. Odds
ratios, conﬁdence intervals (CI), and signiﬁcance levels
were reported. RESULTS: Compared with Caucasian
people, African-American and Hispanic individuals with
hypertension were at signiﬁcantly higher risk of receiving
no antihypertensive medication therapy (OR: 1.39, CI:
1.13–1.71), and (OR: 1.41, CI: 1.10–1.80), respectively,
even after controlling for potential confounders. Within
different classes of antihypertensive medications, African
Americans had signiﬁcantly lower use of Beta-blockers 
or ACE inhibitors as monotherapy (OR: 0.41, CI:
0.27–0.61) and (OR: 0.50, CI: 0.34–0.75) respectively.
This ﬁnding is consistent with hypertension treatment
guidelines recommended by the Fifth Joint National
Committee on the Detection, Evaluation, and Treatment
of High Blood Pressure. Individuals with coexisting dis-
eases, including diabetes (OR: 1.51, CI: 1.24–1.85), con-
gestive heart failure (OR: 5.11, CI: 3.06–8.53), angina
(OR: 2.65, CI: 1.57–4.50), and renal diseases (OR: 2.74,
CI: 1.17–6.44) had substantially higher rates of receiv-
ing combination therapy. CONCLUSIONS: Substantial
racial variations in the utilization of antihypertensive
medications can not simply be explained by demographic
and socioeconomic differences across different racial
groups. Efforts should be made to improve the medica-
tion treatment rate of hypertension among African 
Americans and Hispanics.
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